Myeloid-derived suppressor cells (MDSCs) are one of the major negative regulators in tumor
microenvironment (TME) due to their potent immunosuppressive capacity. MDSCs are the …

Breast cancer, the most frequent female malignancy, is often curable when detected at an
early stage. The treatment of metastatic breast cancer is more challenging and may be …

The triggering receptor expressed on myeloid cell 1 (TREM1) plays a critical role in
development of chronic inflammatory disorders and the inflamed tumor microenvironment …

Internal tandem duplication mutations in fms-like tyrosine kinase 3 (FLT3-ITD) are recurrent
in acute myeloid leukemia (AML) and increase the risk of relapse. Clinical responses to …

Simple Summary Immune checkpoint inhibitor (ICI) therapy has recently become the
standard treatment for advanced hepatocellular carcinoma (HCC); however, clinical …

Myeloid‐derived suppressor cells (MDSCs) are an immature group of myeloid‐derived cells
generated from myeloid cell precursors in the bone marrow. MDSCs appear almost …

Myeloid-derived suppressor cells (MDSCs) hinder antitumor immunity in multiple cancer
types. While brequinar (BRQ), an inhibitor of dihydroorotate dehydrogenase, shows …

Tissue-resident macrophages (TRMs) are abundant immune cells within pre-metastatic
sites, yet their functional contributions to metastasis remain incompletely understood. Here …

Emerging evidence suggests that local tumor radiotherapy reshapes the repertoire of
circulating myeloid-derived suppressor cells (MDSCs) and leads to their infiltration into the …

Myeloid cells are increasingly being recognized as central players orchestrating or
suppressing antitumor immune responses. With the advent of high-resolution analytical …